Table 2. Univariate and multivariate logistic regression for recurrence within 9 months.
| Variable | Univariate regression | Multivariate regression | |||
|---|---|---|---|---|---|
| Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | ||
| Age | 0.99 (0.97–1.01) | 0.298 | – | – | |
| Sex | – | – | |||
| M | 0.81 (0.45–1.44) | 0.469 | |||
| F | – | – | |||
| Child’s grading | – | – | |||
| A | 0.48 (0.17–1.32) | 0.155 | |||
| B/C | – | – | |||
| Hepatitis B carrier | 0.83 (0.48–1.43) | 0.493 | – | – | |
| Cirrhosis | 0.95 (0.62–1.46) | 0.807 | – | – | |
| No. of comorbidities | 0.91 (0.76–1.08) | 0.275 | – | – | |
| ICG (R15) | 1.01 (0.97–1.05) | 0.638 | – | – | |
| Fibroscan | 1.01 (0.98–1.04) | 0.739 | – | – | |
| AFP ≥90 ug/L | 1.87 (1.20–2.91) | 0.006* | 1.55 (0.96–2.50) | 0.073 | |
| Pre-op TACE | 1.01 (0.48–2.10) | 0.982 | – | – | |
| Pre-op PVE | 0.88 (0.33–2.40) | 0.806 | – | – | |
| For those hepatitis B carrier pre-op antiviral | 0.76 (0.46–1.26) | 0.283 | – | – | |
| Size of tumour ≥3.5 cm | 2.80 (1.73–4.55) | <0.001* | 1.79 (1.05–3.05) | 0.033* | |
| Number of tumour | |||||
| Solitary | 0.36 (0.23–0.57) | <0.001* | 0.64 (0.33–1.25) | 0.190 | |
| Multinodular | – | – | – | – | |
| Recurrent tumour | 1.73 (0.59–5.09) | 0.320 | – | – | |
| Degree of differentiation | – | – | |||
| Well | 0.59 (0.21–1.68) | 0.325 | |||
| Moderate | 1.15 (0.53–2.48) | 0.724 | |||
| Poor | – | – | |||
| Satellite nodules | 3.68 (2.08–6.51) | <0.001* | 1.52 (0.66–3.50) | 0.327 | |
| Macro vascular invasion | 2.79 (1.40–5.60) | 0.004* | 1.45 (0.62–3.37) | 0.393 | |
| Micro vascular invasion | 2.15 (1.32–3.52) | 0.002* | 1.43 (0.80–2.54) | 0.226 | |
| Resection margin (cm) | 0.83 (0.67–1.03) | 0.088 | – | – | |
| Involve margin | 3.92 (1.34–11.43) | 0.012* | 1.63 (0.41–6.41) | 0.488 | |
| Major/minor hepatectomy | – | – | |||
| Major | 0.88 (0.57–1.36) | 0.563 | |||
| Minor | – | – | |||
| Surgical approach | – | – | |||
| Open | 1.46 (0.77–2.76) | 0.245 | |||
| Lap/robotic | – | – | |||
| Hilar clamp applied | 0.96 (0.51–1.81) | 0.904 | – | – | |
| Concomitant RFA or MWA | 2.40 (0.77–7.48) | 0.133 | – | – | |
| Blood loss ≥600 mL | 2.30 (1.47–3.60) | <0.001* | 1.51 (0.89–2.54) | 0.125 | |
| Morbidity | 1.06 (0.66–1.70) | 0.814 | – | – | |
| Blood transfusion | 2.33 (1.21–4.49) | 0.011* | 1.30 (0.59–2.87) | 0.513 | |
| Re-operation | 0.93 (0.20–4.45) | 0.929 | – | – | |
| Post-op hospital stay (days) | 1.00 (0.97–1.04) | 0.966 | – | – | |
| Adjuvant TACE | 1.38 (0.80–2.39) | 0.252 | – | – | |
| Ruptured tumor | 4.84 (2.38–9.87) | <0.001* | 2.48 (1.09–5.61) | 0.030* | |
*, statistically significant. ICG (R15), indocyanine green test (retention rate at 15 minutes). AFP, alpha-feto protein; TACE, transarterial chemoembolization; PVE, portal vein embolization; RFA, radiofrequency ablation; MWA, microwave ablation.